A phase II/III trial to assess the safety, immunogenicity and preliminary efficacy of recombinant human EGF-rP64K/Montanide ISA 51 vaccine administered to patients with non-small-cell lung cancer (NSCLC) after receiving conventional first line chemotherapy

Trial Profile

A phase II/III trial to assess the safety, immunogenicity and preliminary efficacy of recombinant human EGF-rP64K/Montanide ISA 51 vaccine administered to patients with non-small-cell lung cancer (NSCLC) after receiving conventional first line chemotherapy

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 29 Sep 2011

At a glance

  • Drugs BV NSCLC 001 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top